BR0101332A - Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80 - Google Patents

Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80

Info

Publication number
BR0101332A
BR0101332A BR0101332-7A BR0101332A BR0101332A BR 0101332 A BR0101332 A BR 0101332A BR 0101332 A BR0101332 A BR 0101332A BR 0101332 A BR0101332 A BR 0101332A
Authority
BR
Brazil
Prior art keywords
polysorbate
salts
cyclosporine
combination
aqueous solution
Prior art date
Application number
BR0101332-7A
Other languages
English (en)
Inventor
Guido Di Napoli
Original Assignee
Medidom Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medidom Lab filed Critical Medidom Lab
Publication of BR0101332A publication Critical patent/BR0101332A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO OFTáLMICA TóPICA NA FORMA DE UMA SOLUçãO AQUOSA, E, USO DE UMA CICLOSPORINA EM ASSOCIAçãO COM áCIDO HIALURÈNICO OU UM DE SEUS SAIS E COM POLISORBATO 80". Uma formulação oftálmica tópica na forma de uma solução aquosa compreendendo uma ciclosporina, ácido hialurónico ou um de seus sais, e polisorbato 80 é descrito.
BR0101332-7A 2000-04-07 2001-04-06 Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80 BR0101332A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH6942000 2000-04-07

Publications (1)

Publication Number Publication Date
BR0101332A true BR0101332A (pt) 2001-11-06

Family

ID=4529494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0101332-7A BR0101332A (pt) 2000-04-07 2001-04-06 Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80

Country Status (19)

Country Link
US (2) US6677304B2 (pt)
EP (1) EP1142566B1 (pt)
JP (1) JP2001316284A (pt)
CN (1) CN1185009C (pt)
AR (1) AR028291A1 (pt)
AT (1) ATE250924T1 (pt)
AU (1) AU778858B2 (pt)
BR (1) BR0101332A (pt)
CA (1) CA2342133C (pt)
CZ (1) CZ294385B6 (pt)
DE (1) DE60100866T2 (pt)
DK (1) DK1142566T3 (pt)
ES (1) ES2206363T3 (pt)
IL (1) IL142268A (pt)
PL (1) PL201055B1 (pt)
PT (1) PT1142566E (pt)
SK (1) SK285220B6 (pt)
TR (1) TR200302105T4 (pt)
ZA (1) ZA200102769B (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
FR2848106B1 (fr) * 2002-12-06 2006-11-17 Oreal Composition de teinture pour fibres keratiniques comprenant un alcool gras non oxyalkylene, un colorant d'oxydation, un polymere associatif et un amide d'une alcanolamine et d'un acide gras en c14-c30.
US7326256B2 (en) 2002-12-06 2008-02-05 L'ORéAL S.A. Composition for the oxidation dyeing of keratin fibers, comprising at least one non-oxyalkenylated fatty alcohol, at least one oxidation dye, at least one associative polymer, and at least one amide of an alkanolamine and a C14-C30 fatty acid
JP2004262777A (ja) * 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
WO2004096261A1 (es) * 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN100548271C (zh) * 2004-01-20 2009-10-14 阿勒根公司 用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
WO2006067608A1 (en) * 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CN100478025C (zh) * 2005-03-25 2009-04-15 中国科学院上海药物研究所 一种环孢菌素a眼用微乳制剂及其制备方法
CA2611909C (en) * 2005-07-01 2014-01-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition for treatment of corneal disease
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
KR101411067B1 (ko) 2005-10-12 2014-06-27 세이가가쿠 고교 가부시키가이샤 점막에 적용하는 작용제 및 그것의 제조 방법
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
WO2007095486A1 (en) * 2006-02-13 2007-08-23 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US20070212420A1 (en) * 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
WO2008002582A2 (en) * 2006-06-27 2008-01-03 Riolan Technologies, Inc. Ultraviolet absorbing ophthalmic compositions
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
JP2010522774A (ja) * 2007-03-30 2010-07-08 フォベア、ファルマスティカル、ソシエテ、アノニム 血管新生眼疾患を治療するための方法
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
US8435544B2 (en) 2007-10-08 2013-05-07 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
GB0904423D0 (en) * 2009-03-14 2009-04-29 Univ Strathclyde Improving the solubility of chemicals
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010144194A1 (en) 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US20130123194A1 (en) * 2011-11-15 2013-05-16 Allergan, Inc. Autoclavable suspensions of cyclosporin a form 2
US8785394B2 (en) * 2011-11-15 2014-07-22 Allergan, Inc. Sustained action formulation of cyclosporin form 2
FR2988297B1 (fr) * 2012-03-22 2014-03-28 Thea Lab Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
EP4137139A1 (en) 2013-07-10 2023-02-22 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
BR112017001017A2 (pt) * 2014-07-18 2018-01-23 Allergan Inc composições em suspensão de ciclosporina a para injeção subconjuntival e periocular
ES2871199T3 (es) 2015-09-24 2021-10-28 Matrix Biology Inst Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas
KR101635915B1 (ko) * 2016-02-15 2016-07-04 삼천당제약주식회사 사이클로스포린과 히알루론산 또는 이의 염을 포함하는 수용액 형태의 안과용 조성물
ES2909998T3 (es) * 2016-10-14 2022-05-11 I Com Medical Gmbh Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2019060696A1 (en) * 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
CA3095460A1 (en) * 2018-03-29 2019-10-03 Mati Therapeutics, Inc. Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
CN113473970A (zh) * 2018-12-27 2021-10-01 瑟菲斯眼科股份有限公司 用以治疗眼表疾病的眼科药物组合物和方法
WO2021008668A1 (en) 2019-07-12 2021-01-21 Pharmathen S.A. Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine
BR112022009710A2 (pt) 2019-11-22 2022-08-09 Incyte Corp Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
EP3988122A4 (en) * 2019-12-17 2023-01-18 Yizhou (Shanghai) Biological Medicine Co, Ltd. USE OF TRANSTHYRETIN FOR INTRODUCTION TO THE EYE AND MAKING DROPS
KR20220157405A (ko) * 2020-03-23 2022-11-29 키오라 파마슈티칼스, 인크. 안구 병태의 치료를 위한 조성물 및 방법
GR1010012B (el) 2020-05-12 2021-05-27 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
US11510930B2 (en) * 2020-08-26 2022-11-29 Somerset Therapeutics, Llc Gatifloxacin, prednisolone, and bromfenac compositions and methods
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2022240598A1 (en) 2021-05-10 2022-11-17 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
TWI868812B (zh) * 2022-07-20 2025-01-01 日商旭化成股份有限公司 玻尿酸衍生物醫藥組合物及醫藥組合物之製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US592048A (en) * 1897-10-19 Drill-press
KR920003601B1 (ko) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5739105A (en) * 1994-06-01 1998-04-14 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
JPH1160505A (ja) * 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd 防腐組成物

Also Published As

Publication number Publication date
DE60100866D1 (de) 2003-11-06
CN1317342A (zh) 2001-10-17
EP1142566B1 (fr) 2003-10-01
TR200302105T4 (tr) 2004-02-23
US6953776B2 (en) 2005-10-11
PT1142566E (pt) 2004-02-27
EP1142566A1 (fr) 2001-10-10
ATE250924T1 (de) 2003-10-15
PL201055B1 (pl) 2009-03-31
AU3340401A (en) 2001-10-11
PL346926A1 (en) 2001-10-08
DK1142566T3 (da) 2004-02-09
CA2342133A1 (en) 2001-10-07
ES2206363T3 (es) 2004-05-16
IL142268A (en) 2007-08-19
DE60100866T2 (de) 2004-07-29
SK285220B6 (sk) 2006-09-07
AU778858B2 (en) 2004-12-23
CZ294385B6 (cs) 2004-12-15
SK4602001A3 (en) 2001-11-06
JP2001316284A (ja) 2001-11-13
AR028291A1 (es) 2003-04-30
US20040106546A1 (en) 2004-06-03
CN1185009C (zh) 2005-01-19
IL142268A0 (en) 2002-03-10
CA2342133C (en) 2011-02-01
US20010041671A1 (en) 2001-11-15
CZ20011229A3 (cs) 2001-11-14
ZA200102769B (en) 2001-10-05
US6677304B2 (en) 2004-01-13

Similar Documents

Publication Publication Date Title
PT1142566E (pt) Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
CO5190689A1 (es) Sales de tramadol formadas por tramadol y un edulcorante y formas farmaceuticas que contienen dichas sales
BR9815609A (pt) Artigo absorvente com uma abertura para fezes na camada superior
BRPI0407723A (pt) artigo absorvente com gravação em relevo ao longo do perìmetro
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
BR0113751A (pt) Composições cosméticas e farmacêuticas e seus empregos
ES2111547T3 (es) Comprimido de liberacion prolongada.
BR0210013A (pt) Gel oftálmico de pirenzepina
DK0907365T3 (da) Hidtil ukendt formulering
ATE248187T1 (de) Echinocandin-kohlenhydrate-komplexe
BR0005824A (pt) Sais de alquilespiroborato para uso em células eletroquìmicas
BR9801056A (pt) Auxiliadora de lavagem para utensílios de plásticos
ATE336243T1 (de) Verwendung von l-carnitin und seinen alkanoyl- derivaten als osmotisches mittel in lösungen für medizinische verwendung
DE60237847D1 (de) Saugfähiger artikel mit verbessertem sitz
TR200401363T4 (tr) DNA viral enfeksiyonlarının tedavisi
BR9813994A (pt) Solução oftalmicamente segura para desinfetar lentes de contato e seu uso
BR0014498A (pt) Artigos elásticos e uso dos mesmos
BR0010150A (pt) Solução oral de prucalopride
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
SE0001916D0 (sv) Novel formulation
BR0107471A (pt) Airbag em formato de polìgono de doze lados
BR0010499A (pt) Agentes endoparasiticidas
ES2131482B1 (es) Formulacion acuosa de bambuterol.
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time